Celldex Therapeutics Inc. (NASDAQ: CLDX) started the day on Wednesday, with a price decrease of -0.31% at $28.67, before settling in for the price of $28.76 at the close. Taking a more long-term approach, CLDX posted a 52-week range of $22.11-$53.18.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare sector firm’s twelve-monthly sales growth has been 30.09% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was 27.41%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 16.47%. This publicly-traded company’s shares outstanding now amounts to $66.29 million, simultaneously with a float of $64.21 million. The organization now has a market capitalization sitting at $1.90 billion. At the time of writing, stock’s 50-day Moving Average stood at $35.89, while the 200-day Moving Average is $38.14.
Celldex Therapeutics Inc. (CLDX) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Celldex Therapeutics Inc.’s current insider ownership accounts for 3.14%, in contrast to 103.47% institutional ownership. According to the most recent insider trade that took place on Jun 14 ’24, this organization’s SVP AND CFO sold 17,172 shares at the rate of 35.42, making the entire transaction reach 608,315 in total value, affecting insider ownership by 28,125. Preceding that transaction, on Jun 14 ’24, Company’s SR. VP & CPDO sold 30,000 for 34.87, making the whole transaction’s value amount to 1,045,962. This particular insider is now the holder of 9,074 in total.
Celldex Therapeutics Inc. (CLDX) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.69 per share during the current fiscal year.
Celldex Therapeutics Inc.’s EPS increase for this current 12-month fiscal period is 16.47% and is forecasted to reach -3.00 in the upcoming year.
Celldex Therapeutics Inc. (NASDAQ: CLDX) Trading Performance Indicators
Let’s observe the current performance indicators for Celldex Therapeutics Inc. (CLDX). It’s Quick Ratio in the last reported quarter now stands at 29.36. The Stock has managed to achieve an average true range (ATR) of 1.78. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 228.98.
In the same vein, CLDX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -2.74, a figure that is expected to reach -0.67 in the next quarter, and analysts are predicting that it will be -3.00 at the market close of one year from today.
Technical Analysis of Celldex Therapeutics Inc. (CLDX)
If we take a close look at the recent performances of Celldex Therapeutics Inc. (NASDAQ: CLDX), its last 5-days Average volume was 0.83 million that shows plunge from its year to date volume of 0.85 million. During the previous 9 days, stock’s Stochastic %D was recorded 28.84% While, its Average True Range was 1.52.
Raw Stochastic average of Celldex Therapeutics Inc. (CLDX) in the period of the previous 100 days is set at 5.95%, which indicates a major fall in contrast to 27.95% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 34.97% that was lower than 57.63% volatility it exhibited in the past 100-days period.
